查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790178

美国即时诊断分子诊断市场规模、份额和趋势分析报告：按技术、应用、检测地点、最终用途和细分市场预测，2025 年至 2033 年

U.S. Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Test Location, By Application, By Technology, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国POC 分子诊断市场价值将达到 32.3 亿美元，预计 2025 年至 2033 年的复合年增长率为 5.45%。

该市场以快速、分散的分子检测为中心，旨在支持在护理点或护理点附近更快地做出临床决策。由于门诊病人和急诊护理环境中对快速、准确结果的需求，这些诊断平台在传染病筛检、呼吸道感染疾病和性行为感染感染检测等应用中的应用日益广泛。

市场成长的动力源自于传统实验室之外，尤其是在急诊和诊所，对快速便捷检测的需求日益增长。感染疾病病例的增加以及对快速结果的需求，推动了照护现场(POC) 分子检测的使用。可携式PCR 仪和简易样本处理工具等新技术使这些检测更加准确、更容易使用。此外，新冠疫情爆发后，人们对快速检测的关注也推动了市场进一步成长。

此外，基层医疗机构中的即时检测 (POC) 分子诊断涵盖了从基础血糖检测到更复杂的凝血检查等广泛的应用。美国许多诊所正在从传统的实验室检测过渡到即时检测 (POC) 方法，这有助于减少与样本处理和运输相关的延误。这种转变使得在就诊时能够更快地做出决策，从而更快地获得结果、降低成本并改善护理。

此外，预计美国老龄人口的成长将推动POC分子诊断产业的成长。根据美国国家癌症研究所的SEER资料库，38%的女性和43%的男性在一生中会罹患癌症。近三分之二的新发癌症病例发生在65岁或以上的人群中，这表明癌症的可能性随着老龄化的增长而增加。分子诊断在癌症、感染疾病和心臟病的治疗中发挥重要作用，对于老年人的及时诊断和治疗至关重要。

此外，市场上的公司正在积极开发新的即时检测（POC）分子检测产品，以满足日益增长的诊断需求。 2023年4月，总部位于洛杉矶的Curative公司宣布其分拆公司Sensible Diagnostics将推出桌面PCR检测平台。该系统旨在约10分钟内提供实验室层级的检测结果，成本与侧流抗原检测相当。该系统旨在用于零售诊所、紧急护理中心和其他靠近患者的场所。

2023年8月，Sensible Diagnostics 获得了约100万美元的NIH RADx Tech奖项，用于支持开髮用于即时诊断的多重呼吸道病毒检测组。这些努力反映了对快速、准确的分子检测解决方案的持续投资，这些解决方案支持及时诊断并改善分散医疗环境中的临床工作流程。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章美国POC 分子诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国POC分子诊断市场的分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国POC 分子诊断市场：按技术、估计和趋势分析

  • 波动分析：按技术
  • 基于PCR
    • 基于PCR的市场，2021-2033
  • 基于基因定序
    • 基因定序市场，2021-2033
  • 基于杂合反应
    • 杂合反应动力市场，2021-2033
  • 基于微阵列
    • 2021-2033年微阵列市场

第五章：美国POC 分子诊断市场的应用、估计与趋势分析

  • 波动分析：按应用
  • 感染疾病
    • 感染疾病市场，2021-2033年
    • HIV POC
    • 困难梭状芽孢桿菌POC
    • HBV POC
    • 肺炎或链球菌感染疾病
    • 呼吸道融合细胞病毒(RSV) 临床验证
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 结核病和抗药性结核病的即时治疗
    • HSV POC
    • 其他的
  • 肿瘤学
    • 肿瘤学市场 2021-2033
  • 血液学
    • 血液学市场 2021-2033
    • 全血球计数（CBC）
    • 凝血酶原时间（PT）
    • 部份凝血活酵素时间（PTT）
    • 其他的
  • 产前检查
    • 产前检测市场，2021-2033年
  • 内分泌学
    • 内分泌学市场，2021-2033
  • 其他的
    • 其他市场，2021-2033

第六章：美国POC 分子诊断市场（按测试地点、估计和趋势分析）

  • 变异分析：依测试地点
  • OTC
    • 场外交易市场，2021-2033年
  • POC
    • POC市场，2021-2033年

第七章美国POC分子诊断市场：依最终用途的估计和趋势分析

  • 变化分析：依最终用途
  • 分散式实验室
    • 分散式实验室市场，2021-2033
  • 医院
    • 医院市场，2021-2033
  • 居家护理
    • 家庭护理市场，2021-2033
  • 辅助生活医疗设施
    • 辅助医疗设施市场，2021-2033
  • 其他的
    • 其他市场，2021-2033

第八章 竞争态势

  • 公司分类
  • 战略地图
    • 推出新产品和服务
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市场占有率分析（2024年）
  • 公司热图分析
  • 公司简介
    • QIAGEN
    • DANAHER
    • THERMO FISHER SCIENTIFIC, INC.
    • BD
    • F. HOFFMAN-LA ROCHE AG
    • CHARLES RIVER LABORATORIES
    • QUEST DIAGNOSTICS INCORPORATED
    • BIO-RAD LABORATORIES, INC.
    • HOLOGIC INC.
    • AGILENT TECHNOLOGIES, INC.
Product Code: GVR-4-68040-203-1

Market Size & Trends:

The U.S. point of care molecular diagnostics market size was estimated at USD 3.23 billion in 2024 and is expected to grow at a CAGR of 5.45% from 2025 to 2033. The market is centered around rapid and decentralized molecular testing that supports quicker clinical decisions at or near the site of patient care. These diagnostic platforms are increasingly adopted for applications such as infectious disease screening, respiratory tract infections, and sexually transmitted disease detection, driven by the need for immediate and accurate results in outpatient and emergency settings.

Market growth is supported by the rising demand for quick and easy testing outside traditional labs, especially in emergency rooms and clinics. The growing number of infectious disease cases and the need for fast results are pushing the use of point-of-care molecular tests. New technologies, such as portable PCR machines and simple sample processing tools, make these tests more accurate and easier to use. In addition, the focus on faster testing after the COVID-19 pandemic is helping the market grow further.

Moreover, point-of-care molecular diagnostics in primary care settings cover a wide range of uses, from basic glucose tests to more complex blood clotting checks. Many clinics across the U.S. are moving away from traditional lab-based testing to point-of-care methods, which help reduce delays linked to sample handling and transport. This switch allows for quicker decisions during patient visits, leading to faster results, lower costs, and improved care.

In addition, the growing elderly population is expected to support the growth of the U.S. point of care molecular diagnostics industry. Based on the U.S. National Cancer Institute's SEER Database, 38% of women and 43% of men are likely to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are found in people aged 65 and older, showing that aging increases vulnerability to cancer. Molecular diagnostics play a key role in managing cancer, infectious diseases, and heart conditions, making them an essential part of timely diagnosis and treatment in older adults.

Furthermore, market players are actively developing new point-of-care molecular testing products to address growing diagnostic needs. In April 2023, Curative, Inc., based in Los Angeles, announced the spin-off of Sensible Diagnostics to commercialize a desktop PCR testing platform. This system is designed to deliver lab-quality results in approximately 10 minutes, at a cost similar to lateral flow antigen tests. It is intended for use in retail clinics, urgent care centers, and other near-patient environments.

In August 2023, Sensible Diagnostics received a NIH RADx Tech award of approximately USD 1 million to support the development of a multiplex respiratory viral panel for point-of-care use. These efforts reflect growing investment in rapid, accurate molecular testing solutions that support timely diagnosis and improve clinical workflows across decentralized care settings.

U.S. Point of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. point of care molecular diagnostics market report based on application, technology, test location, and end-use:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
    • HIV POC
    • Clostridium difficile POC
    • HBV POC
    • Pneumonia or Streptococcus associated infections
    • Respiratory syncytial virus (RSV) POC
    • HPV POC
    • Influenza/Flu POC
    • HCV POC
    • MRSA POC
    • TB and drug-resistant TB POC
    • HSV POC
    • Other Infectious Diseases
  • Oncology
  • Hematology
    • Complete blood count (CBC)
    • Prothrombin time (PT)
    • Partial Thromboplastin Time (PTT)
    • Others
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Location
    • 1.2.2. Application
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in the U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Location and Application Snapshot
    • 2.2.2. Technology Snapshot
    • 2.2.3. End Use Snapshot
  • 2.3. Competitive Insights

Chapter 3. U.S. Point-of-Care Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing demand for rapid and decentralized testing
      • 3.2.1.2. Rising prevalence of infectious diseases
      • 3.2.1.3. Technological advancements in molecular platforms
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of molecular POC devices and consumables
      • 3.2.2.2. Regulatory and quality assurance challenges
  • 3.3. U.S. Point-of-Care Molecular Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based market, 2021 - 2033 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based market, 2021 - 2033 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases market, 2021 - 2033 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC market, 2021 - 2033 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC market, 2021 - 2033 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC market, 2021 - 2033 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC market, 2021 - 2033 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC market, 2021 - 2033 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC market, 2021 - 2033 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC market, 2021 - 2033 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC market, 2021 - 2033 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC market, 2021 - 2033 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology market, 2021 - 2033 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology market, 2021 - 2033 (USD Million)
    • 5.4.2. Complete blood count (CBC)
      • 5.4.2.1. Complete blood count (CBC) market, 2021 - 2033 (USD Million)
    • 5.4.3. Prothrombin time (PT)
      • 5.4.3.1. Prothrombin time (PT) market, 2021 - 2033 (USD Million)
    • 5.4.4. Partial Thromboplastin Time (PTT)
      • 5.4.4.1. Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Others market, 2021 - 2033 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing market, 2021 - 2033 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC market, 2021 - 2033 (USD Million)
  • 6.3. POC
    • 6.3.1. POC market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs market, 2021 - 2033 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals market, 2021 - 2033 (USD Million)
  • 7.4. Home-care
    • 7.4.1. Home-care market, 2021 - 2033 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Products and Services Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. QIAGEN
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Products and Services Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. DANAHER
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Products and Services Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. THERMO FISHER SCIENTIFIC, INC.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Products and Services Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BD
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Products and Services Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. F. HOFFMAN-LA ROCHE AG
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Products and Services Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CHARLES RIVER LABORATORIES
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Products and Services Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. QUEST DIAGNOSTICS INCORPORATED
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Products and Services Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. BIO-RAD LABORATORIES, INC.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Products and Services Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. HOLOGIC INC.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Products and Services Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AGILENT TECHNOLOGIES, INC.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Products and Services Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Point-of-Care Molecular Diagnostics market, by test location, 2021 - 2033 (USD Million)
  • Table 3 U.S. Point-of-Care Molecular Diagnostics market, by application, 2021- 2033 (USD Million)
  • Table 4 U.S. Point-of-Care Molecular Diagnostics market, by technology, 2021 - 2033 (USD Million)
  • Table 5 U.S. Point-of-Care Molecular Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in the U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Point-of-Care Molecular Diagnostics market: market outlook
  • Fig. 10 U.S. Point-of-Care Molecular Diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Point-of-Care Molecular Diagnostics market driver impact
  • Fig. 16 U.S. Point-of-Care Molecular Diagnostics market restraint impact
  • Fig. 17 U.S. Point-of-Care Molecular Diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. Point-of-Care Molecular Diagnostics market: Application movement analysis
  • Fig. 19 U.S. Point-of-Care Molecular Diagnostics market: Application outlook and key takeaways
  • Fig. 20 Point-of-Care Molecular Diagnostics Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 21 Point-of-Care Molecular Diagnostics HIV POC market, 2021 - 2033 (USD Million)
  • Fig. 22 Point-of-Care Molecular Diagnostics Clostridium difficile POC market, 2021 - 2033 (USD Million)
  • Fig. 23 Point-of-Care Molecular Diagnostics HBV POC market, 2021 - 2033 (USD Million)
  • Fig. 24 Point-of-Care Molecular Diagnostics Pneumonia or Streptococcus associated infections market, 2021 - 2033 (USD Million)
  • Fig. 25 Point-of-Care Molecular Diagnostics Respiratory syncytial virus (RSV) POC market, 2021 - 2033 (USD Million)
  • Fig. 26 Point-of-Care Molecular Diagnostics HPV POC market, 2021 - 2033 (USD Million)
  • Fig. 27 Point-of-Care Molecular Diagnostics Influenza/Flu POC market, 2021 - 2033 (USD Million)
  • Fig. 28 Point-of-Care Molecular Diagnostics HCV POC market, 2021 - 2033 (USD Million)
  • Fig. 29 Point-of-Care Molecular Diagnostics MRSA POC market, 2021 - 2033 (USD Million)
  • Fig. 30 Point-of-Care Molecular Diagnostics TB and drug-resistant TB POC market, 2021 - 2033 (USD Million)
  • Fig. 31 Point-of-Care Molecular Diagnostics HSV POC market, 2021 - 2033 (USD Million)
  • Fig. 32 Point-of-Care Molecular Diagnostics Other Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 33 Point-of-Care Molecular Diagnostics Oncology market, 2021 - 2033 (USD Million)
  • Fig. 34 Point-of-Care Molecular Diagnostics Hematology market, 2021 - 2033 (USD Million)
  • Fig. 35 Point-of-Care Molecular Diagnostics Complete blood count (CBC) market, 2021 - 2033 (USD Million)
  • Fig. 36 Point-of-Care Molecular Diagnostics Prothrombin time (PT) market, 2021 - 2033 (USD Million)
  • Fig. 37 Point-of-Care Molecular Diagnostics Partial Thromboplastin Time (PTT) market, 2021 - 2033 (USD Million)
  • Fig. 38 Point-of-Care Molecular Diagnostics Others market, 2021 - 2033 (USD Million)
  • Fig. 39 Point-of-Care Molecular Diagnostics Prenatal Testing market, 2021 - 2033 (USD Million)
  • Fig. 40 Point-of-Care Molecular Diagnostics Endocrinology market, 2021 - 2033 (USD Million)
  • Fig. 41 Point-of-Care Molecular Diagnostics Other Applications market, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Point-of-Care Molecular Diagnostics market: Technology movement Analysis
  • Fig. 43 U.S. Point-of-Care Molecular Diagnostics market: Technology outlook and key takeaways
  • Fig. 44 Point-of-Care Molecular Diagnostics PCR-based market, 2021 - 2033 (USD Million)
  • Fig. 45 Point-of-Care Molecular Diagnostics Genetic Sequencing-based market, 2021 - 2033 (USD Million)
  • Fig. 46 Point-of-Care Molecular Diagnostics Hybridization-based market, 2021 - 2033 (USD Million)
  • Fig. 47 Point-of-Care Molecular Diagnostics Microarray-based market, 2021 - 2033 (USD Million)
  • Fig. 48 Point-of-care Molecular Diagnostics revenue share, by test location, 2021 - 2033
  • Fig. 49 Point-of-Care Molecular Diagnostics OTC market, 2021 - 2033 (USD Million)
  • Fig. 50 Point-of-Care Molecular Diagnostics POC market, 2021 - 2033 (USD Million)
  • Fig. 51 U.S. Point-of-Care Molecular Diagnostics market: End Use movement analysis
  • Fig. 52 U.S. Point-of-Care Molecular Diagnostics market: End Use outlook and key takeaways
  • Fig. 53 Point-of-Care Molecular Diagnostics Decentralized Labs market, 2021 - 2033 (USD Million)
  • Fig. 54 Point-of-Care Molecular Diagnostics Hospitals market, 2021 - 2033 (USD Million)
  • Fig. 55 Point-of-Care Molecular Diagnostics Home-care market, 2021 - 2033 (USD Million)
  • Fig. 56 Point-of-Care Molecular Diagnostics Assisted Living Healthcare Facilities market, 2021 - 2033 (USD Million)
  • Fig. 57 Point-of-Care Molecular Diagnostics Other uses market, 2021 - 2033 (USD Million)
  • Fig. 58 U.S. Point-of-Care Molecular Diagnostics market share and leading players
  • Fig. 59 U.S. market share and leading players
  • Fig. 60 U.S. SWOT
  • Fig. 61 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 62 Market share of key market players- U.S. Point-of-Care Molecular Diagnostics market